Answers are grounded in this paper and cite their sources.
Background: Ovarian cancer remains difficult to control because of tumour heterogeneity, recurrent disease, therapeutic resistance, and an immunosuppressive tumour microenvironment. Epigenetic plasticity may connect these processes by enabling reversible transcriptional adaptation. This review examines how epigenetic mechanisms contribute to drug resistance and immune evasion in ovarian cancer and evaluates their therapeutic relevance. Methods: We conducted a narrative synthesis of evidence concerning DNA methylation, histone modifications, chromatin remodelling, and non-coding RNAs in ovarian cancer. Mechanistic findings were integrated with biomarker studies, preclinical therapeutic investigations, and clinical trials, while distinguishing ovarian cancer-specific evidence from observations extrapolated from other malignancies. Results: Epigenetic dysregulation influences DNA repair, homologous recombination, cancer stemness, epithelial–mesenchymal transition, apoptotic escape, metabolic adaptation, antigen presentation, interferon signalling, chemokine expression, immune checkpoints, and tumour–immune interactions. DNA methylation and H3K27me3-associated regulation provide some of the strongest ovarian cancer-specific mechanistic evidence linking epigenetic plasticity to platinum or PARP-inhibitor response and immune-cell recruitment. Non-coding RNAs and emerging histone modifications further regulate resistant and immune-evasive phenotypes, although much of this evidence remains preclinical. Early clinical studies of DNA-demethylating agents combined with platinum chemotherapy, immune checkpoint inhibitors, or cancer vaccines demonstrate biological activity in selected settings but have not established consistent or durable clinical benefit. Conclusions: Epigenetic plasticity represents a potentially targetable, context-dependent link between therapeutic resistance and immune evasion in ovarian cancer. Translation will require histotype-specific models, longitudinal epigenomic and immune profiling, predictive biomarkers, and biomarker-guided trials that account for target selectivity, treatment sequencing, toxicity, and effects on normal immune cells.
No takes yet. Share an insight, caveat, or question.
Kandi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: